Development and validation of a cost-utility model for Type1 diabetes mellitus

被引:8
|
作者
Wolowacz, S. [1 ]
Pearson, I. [1 ]
Shannon, P. [2 ]
Chubb, B. [3 ]
Gundgaard, J. [4 ]
Davies, M. [5 ]
Briggs, A. [6 ]
机构
[1] RTI Hlth Solut, Hlth Econ, Manchester, Lancs, England
[2] RTI Hlth Solut, Patient Reported Outcomes, Manchester, Lancs, England
[3] Novo Nordisk Ltd, European Hlth Econ & Outcomes Res, Gatwick, W Sussex, England
[4] Novo Nordisk AS, Hlth Econ & HTA, Bagsvaerd, Denmark
[5] Univ Leicester, Diabet Res Ctr, Leicester, Leics, England
[6] Univ Glasgow, Inst Hlth & Wellbeing, Glasgow, Lanark, Scotland
关键词
RISK-FACTORS; COMPLICATIONS; DISEASE; NEUROPATHY; EURODIAB; COHORT; ONSET;
D O I
10.1111/dme.12663
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
AimsTo develop a health economic model to evaluate the cost-effectiveness of new interventions for Type1 diabetes mellitus by their effects on long-term complications (measured through mean HbA(1c)) while capturing the impact of treatment on hypoglycaemic events. MethodsThrough a systematic review, we identified complications associated with Type1 diabetes mellitus and data describing the long-term incidence of these complications. An individual patient simulation model was developed and included the following complications: cardiovascular disease, peripheral neuropathy, microalbuminuria, end-stage renal disease, proliferative retinopathy, ketoacidosis, cataract, hypoglycemia and adverse birth outcomes. Risk equations were developed from published cumulative incidence data and hazard ratios for the effect of HbA(1c), age and duration of diabetes. We validated the model by comparing model predictions with observed outcomes from studies used to build the model (internal validation) and from other published data (external validation). We performed illustrative analyses for typical patient cohorts and a hypothetical intervention. ResultsModel predictions were within 2% of expected values in the internal validation and within 8% of observed values in the external validation (percentages represent absolute differences in the cumulative incidence). ConclusionsThe model utilized high-quality, recent data specific to people with Type1 diabetes mellitus. In the model validation, results deviated less than 8% from expected values. What's new? A simple cost-utility model was developed to evaluate new interventions for Type1 diabetes mellitus by assessing the association between the interventions' effects on mean HbA(1c) and long-term complications and the risk of hypoglycaemic events. High-quality, recently reported data specific to people with Type1 diabetes mellitus were identified by a systematic review. Model validation included review by clinical and economic experts, verification of input data and formulae, and comparison of model predictions with observations from studies used to build the model and other published data.
引用
收藏
页码:1023 / 1035
页数:13
相关论文
共 50 条
  • [21] Development and validation of paired MEDLINE and Embase search filters for cost-utility studies
    Hubbard, Wesley
    Walsh, Nicola
    Hudson, Thomas
    Heath, Andrea
    Dietz, Jeremy
    Rogers, Gabriel
    BMC MEDICAL RESEARCH METHODOLOGY, 2022, 22 (01)
  • [22] DETEMIR IN DIABETES TYPE 2 PATIENTS A COST-UTILITY ANALYSIS, COLOMBIA 2014
    Romero, M.
    Huerfano, L. M.
    Paez, M. L.
    Acero, G.
    VALUE IN HEALTH, 2015, 18 (03) : A63 - A63
  • [23] Cost-utility of empagliflozin in patients with type 2 diabetes at high cardiovascular risk
    Nguyen, Elaine
    Coleman, Craig I.
    Nair, Suresh
    Weeda, Erin R.
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2018, 32 (02) : 210 - 215
  • [24] Urine Heat Shock Protein Levels In Children With Type1 Diabetes Mellitus
    Yilmaz, Alev
    Gedikbasi, Asuman
    Yildrim, Zeynep Yuruk
    Pehlivanoglu, Cemile
    Seker, Basak
    Sucu, Aysegul
    Bundak, Ruveyde
    Emre, Sevinc
    PEDIATRIC NEPHROLOGY, 2014, 29 (09) : 1677 - 1678
  • [25] Cost-utility analysis of insulin glargine compared with NPH insulin in patients with type 1 diabetes in Spain
    Terrés, CR
    Rodríguez, J
    Bolinder, B
    De Pablos, P
    DIABETES, 2004, 53 : A291 - A292
  • [26] COST-UTILITY OF BIPHASIC INSULIN ASPART COMPARED WITH PREMIXED HUMAN INSULIN IN TREATMENT OF TYPE-2 DIABETES MELLITUS IN POLAND
    Szmurlo, D.
    Gurda-Duda, A.
    Rys, P.
    Rutkowski, J.
    Skrzekowska-Baran, I
    Plisko, R.
    Wladysiuk, M.
    VALUE IN HEALTH, 2009, 12 (07) : A409 - A409
  • [27] Cost-utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus
    Davies, M. J.
    Chubb, B. D.
    Smith, I. C.
    Valentine, W. J.
    DIABETIC MEDICINE, 2012, 29 (03) : 313 - 320
  • [28] Cost-effectiveness and cost-utility analysis of type-2 diabetes screening in pharmacies in Iran
    Amirsadri, Mohammadreza
    Torkpour, Elahe
    RESEARCH IN PHARMACEUTICAL SCIENCES, 2023, 18 (02) : 210 - 218
  • [29] THE COST-UTILITY AND BUDGET IMPACT ANALYSIS OF SITAGLIPTIN (JANUVIA®) IN TYPE 2 DIABETES IN POLAND
    Walczak, J.
    Malczak, I
    Panasiuk, A.
    Pawlik, D.
    Lasota, K.
    Stelmachowski, J.
    Nogas, G.
    VALUE IN HEALTH, 2008, 11 (06) : A500 - A500
  • [30] Cost-utility analysis of lifestyle interventions to prevent type 2 diabetes in women with prior gestational diabetes
    Werbrouck, Amber
    Schmidt, Masja
    Putman, Koen
    Annemans, Lieven
    Benhalima, Katrien
    Simoens, Steven
    Verhaeghe, Nick
    EUROPEAN JOURNAL OF PUBLIC HEALTH, 2020, 30 (03): : 396 - 401